Standard of Care Therapy for Transplant Eligible Patients with Multiple Myeloma Based on Risk Stratification

Video Library —April 22, 2020
Charise Gleason, MSN, NP-BC, AOCNP
Advanced Practice Provider Chief, Winship Cancer Institute,
Emory University,
Atlanta, GA
Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma, and PGY2 Oncology Residency Research Coordinator,
Winship Cancer Institute, Emory Healthcare,
Atlanta, GA
Chelsea Sprouse, RN-BSN, MSN, NP-C
Nurse Practitioner, Inpatient and Outpatient Malignant Hematology,
Levine Cancer Institute,
Charlotte, NC

Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C discuss their approach to the care of transplant-eligible patients with multiple myeloma, particularly based on the patients' risk stratification, as well as poor-prognosis cytogenetics including those with (4,14) translocation.

Related Articles
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
|
Video Library
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country